• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

    7/21/25 7:00:00 AM ET
    $BBNX
    $BCAX
    $KMTS
    $MORF
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBNX alert in real time by email

    Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs.

    Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing innovative products across multiple therapeutic areas, including oncology, immunology, rare diseases, medical devices, and precision medicine.

    Fund VIII builds upon the prior success of Omega Funds, resulting in 52 commercialized products being brought to market by Omega portfolio companies. The firm's investments have resulted in 50 exits via M&A, and 47 public listings. Omega's recent M&A exits and IPOs include SoniVie (acquired by Boston Scientific), Scorpion Therapeutics (acquired by Eli Lilly), Kestra Medical Technologies (NASDAQ:KMTS), Beta Bionics (NASDAQ:BBNX), Upstream Bio (NASDAQ:UPB), Bicara Therapeutics (NASDAQ:BCAX), Morphic Therapeutic (NASDAQ:MORF, acquired by Eli Lilly)), EyeBio (acquired by Merck), Imago BioSciences (NASDAQ:IMGO, acquired by Merck)), Amunix Pharmaceuticals (acquired by Sanofi), and Chord Therapeutics (acquired by Merck KGaA).

    "We are very grateful to our investors for the support and trust, particularly given this exceptionally challenging fundraising environment. By exceeding its target size, Fund VIII is a recognition of our investment strategy and track record of consistent exits across market cycles," said Otello Stampacchia, Founder and Managing Director of Omega Funds. "We appreciate the partnership from both our longstanding and new limited partners."

    "As with prior funds, Fund VIII will support management teams in the U.S. and Europe through company creation, early venture rounds, and later-stage financings," said Francesco Draetta, Managing Director of Omega Funds. "We believe our broad investment strategy is well-positioned for navigating this period of macro and policy uncertainty. We look forward to contributing our capital, expertise, and network connectivity in partnering with entrepreneurs, founders, co-investors, and the broader community to transform the standards of care for severe diseases."

    About Omega Funds

    Founded in 2004, Omega Funds is a leading international venture capital firm that creates and invests in life sciences companies that target our world's most urgent medical needs. Omega focuses on identifying and supporting companies through value inflection points across the full arc of innovation, from company formation through clinical milestones and commercial adoption. Omega Funds' portfolio companies have brought 52 commercialized products to market in multiple therapeutic areas, including oncology, rare diseases, precision medicine, medical devices, and others. Please visit www.omegafunds.com for additional information.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250721567050/en/

    Media Contact:

    Michael Beyer

    Harbinger Group

    Tel: 312-961-2502

    E-mail: [email protected]

    Omega Contact:

    Sean Cumiskey

    Head of Investor Relations

    Tel: 617-721-4388

    E-mail: [email protected]

    Get the next $BBNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBNX
    $BCAX
    $KMTS
    $MORF

    CompanyDatePrice TargetRatingAnalyst
    Bicara Therapeutics Inc.
    $BCAX
    8/19/2025$36.00Overweight
    Piper Sandler
    Beta Bionics Inc.
    $BBNX
    6/16/2025$26.00Buy
    Truist
    Beta Bionics Inc.
    $BBNX
    6/12/2025$30.00Buy
    Lake Street
    Beta Bionics Inc.
    $BBNX
    5/30/2025$16.00Neutral
    Goldman
    Beta Bionics Inc.
    $BBNX
    5/30/2025$20.00Outperform
    Wolfe Research
    Bicara Therapeutics Inc.
    $BCAX
    5/23/2025$8.00Underweight → Equal Weight
    Wells Fargo
    Bicara Therapeutics Inc.
    $BCAX
    4/17/2025$8.00Underweight
    Wells Fargo
    Kestra Medical Technologies Ltd.
    $KMTS
    3/31/2025$30.00Buy
    BofA Securities
    More analyst ratings

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

    – Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes – – Data support the potential of verekitug's unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respiratory diseases – WALTHAM, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented structural and mechanistic data showing verekitug

    9/30/25 4:15:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kestra Showcases Cardiac Recovery System Platform at HFSA 2025, Redefining Sudden Cardiac Arrest Risk Management

    KIRKLAND, Wash., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ: KMTS), a wearable medical device and digital healthcare company, today announced its debut at the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting, September 26–29 in Minneapolis, Minnesota. At booth #920, Kestra will feature its Cardiac Recovery System® (CRS) platform, anchored by the ASSURE® Wearable Cardioverter Defibrillator. The CRS platform closes the critical gap in sudden cardiac death protection by pairing protection with actionable insights that support confident care during the high-risk early phase of heart failure recovery. Attendees can explore the CRS platfo

    9/25/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Bicara Therapeutics with a new price target

    Piper Sandler initiated coverage of Bicara Therapeutics with a rating of Overweight and set a new price target of $36.00

    8/19/25 8:33:19 AM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Beta Bionics with a new price target

    Truist initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $26.00

    6/16/25 7:46:03 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on Beta Bionics with a new price target

    Lake Street initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $30.00

    6/12/25 8:09:02 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    SEC Filings

    View All

    SEC Form 144 filed by Bicara Therapeutics Inc.

    144 - Bicara Therapeutics Inc. (0002023658) (Subject)

    9/29/25 4:38:05 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Beta Bionics Inc.

    SCHEDULE 13G - Beta Bionics, Inc. (0001674632) (Subject)

    9/19/25 4:21:13 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Kestra Medical Technologies Ltd.

    10-Q - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

    9/12/25 4:17:17 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Meisner Lara exercised 15,829 shares at a strike of $5.45 and sold $181,875 worth of shares (15,829 units at $11.49) (SEC Form 4)

    4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

    9/17/25 5:01:09 PM ET
    $BCAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Chief Commercial Officer Ford Alfred J Jr bought $340,000 worth of shares (20,000 units at $17.00), increasing direct ownership by 68% to 49,412 units (SEC Form 4)

    4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/15/25 4:30:46 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Amendment: Officer Umberger Traci S bought $229,500 worth of shares (13,500 units at $17.00), increasing direct ownership by 11% to 134,336 units (SEC Form 4)

    4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/15/25 4:17:34 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Amendment: Chief Commercial Officer Ford Alfred J Jr bought $340,000 worth of shares (20,000 units at $17.00), increasing direct ownership by 68% to 49,412 units (SEC Form 4)

    4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/15/25 4:30:46 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Amendment: Officer Umberger Traci S bought $229,500 worth of shares (13,500 units at $17.00), increasing direct ownership by 11% to 134,336 units (SEC Form 4)

    4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/15/25 4:17:34 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Director Cohen Raymond W bought $289,000 worth of shares (17,000 units at $17.00) and was granted 10,909 shares, increasing direct ownership by 215% to 40,903 units (SEC Form 4)

    4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/8/25 5:38:22 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies Appoints Dr. Elizabeth Kwo to Board of Directors

    KIRKLAND, Wash., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Elizabeth Kwo, M.D. as an independent director to its board following her election at the company's annual general meeting of shareholders held earlier this month. "I am pleased to welcome Dr. Kwo to the Kestra board of directors," said Brian Webster, President and CEO of Kestra Medical Technologies. "As a physician, healthcare executive, and entrepreneur, she brings extensive experience building and scaling digital health platforms and advancing data-driven care models to improve patient outcomes.

    9/17/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upstream Bio Inc.

    SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

    11/7/24 9:24:55 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Upstream Bio Inc.

    SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

    10/22/24 4:06:27 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Upstream Bio Inc.

    SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

    10/18/24 6:10:56 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBNX
    $BCAX
    $KMTS
    $MORF
    Financials

    Live finance-specific insights

    View All

    Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results

    KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial Highlights Generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period.Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period.Increased FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. "We had a strong start to fiscal 2026, with our sustained commercial momentum generating revenue growth of over 50% in the first quarter," sai

    9/11/25 4:01:00 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    – In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001) – – Significant and clinically meaningful improvements were observed in key secondary endpoints, including -0.8 (p=0.0003) reduction in nasal congestion score and 76% (p=0.03) reduction in need for surgery or systemic corticosteroids – – No serious adverse events (SAEs) observed; generally well tolerated safety profile consistent with previous studies – – Observed clinical effect on endoscopic NPS in this Phase 2 trial suggests verekit

    9/2/25 6:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025. The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100 mg of verekitug or pl

    9/1/25 5:00:00 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care